Eli Lilly's Gate Bioscience Bet Signals Pipeline Ambitions Beyond Its Metabolic Franchise
Published on 10/07/2026 at 17:21 | Editorial boerse-global.de
Eli Lilly shares climbed 2.9% on Wednesday to trade at EUR 1,058.60, closing to within 4.5% of their 52-week high. The advance extends a steady run of gains for the pharmaceutical group, which has spent recent weeks stacking up clinical and regulatory wins while deepening its bet on early-stage science.
That bet came into sharper focus Monday, when the Indianapolis-based company broadened a research and licensing pact with Gate Bioscience — an agreement first struck in 2025 — by adding one Molecular Gate target and securing an option on a second. Once milestone payments and other fees are tallied, the deal could be worth upwards of $870 million.
How the Molecular Gate Platform Works
Under the expanded terms, Gate Bioscience will receive an undisclosed upfront payment, research funding and potential milestone payments, plus tiered royalties on future global net sales. Should Eli Lilly elect to add the second target, a further payment falls due.
Gate Bioscience will handle the initial drug discovery work using its proprietary platform, while Eli Lilly picks up worldwide exclusive rights to develop, manufacture and commercialize any resulting therapies. The technology relies on orally available small molecules — the so-called Molecular Gates — designed to block the transport of disease-causing proteins through the cellular Sec61 channel, thereby triggering their degradation. Gate Bioscience puts the platform's theoretical reach at roughly 4,000 relevant targets spanning immunology, neuroscience and cardiometabolic disease.
Should investors sell immediately? Or is it worth buying Eli Lilly?
For Eli Lilly, the arrangement offers early access to a platform that could push the boundaries of bioavailable small molecules well beyond conventional binding sites. No specific development candidates or clinical timelines tied to the collaboration have been disclosed so far.
A Pipeline Built on Deals
The Gate Bioscience tie-up fits a broader strategy of widening the pipeline through partnerships and acquisitions. According to GlobalData, Eli Lilly sank close to $32 billion into takeovers alone in the year through early October.
Those outlays sit alongside formidable organic momentum in incretin therapies. In the second quarter of 2026, sales of the diabetes drug Mounjaro surged 91% year over year to $9.9 billion, while the obesity treatment Zepbound contributed $4.9 billion. Combined, the two products accounted for about 64% of total quarterly revenue, which reached $22.97 billion.
Regulatory and Clinical Momentum
Beyond dealmaking, Eli Lilly has logged a string of operational milestones. On Friday, the FDA granted approval for an additional indication for the cancer drug Jaypirca, covering adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma who do not carry a 17p deletion.
Earlier, on September 30, the company reported primary and secondary endpoints from the Phase 3b ADtouch trial of EBGLYSS, showing improvements in skin clearance on the hands and feet as well as reductions in pain and itching after 16 weeks of treatment. A separate FDA clearance on September 25 extended Olumiant to severe forms of alopecia areata in patients aged twelve and older.
Eli Lilly at a turning point? This analysis reveals what investors need to know now.
Metabolic research has produced notable data as well. Late in September, Eli Lilly unveiled results from the Phase 2b EloraTZP study in adults with type 2 diabetes who were overweight or obese. The highest-dose combination achieved an average weight loss of 23.3% after 48 weeks, versus 14.8% for tirzepatide alone on the efficacy estimand over the same period.
The company also plans to present 21 scientific posters at an upcoming clinical dermatology conference, including new analyses of the antibody EBGLYSS and an exploratory look at combining Taltz with Zepbound in psoriasis and obesity.
Investors will get their next read on the business on October 29, when Eli Lilly is due to report quarterly results, according to media reports.
Ad
Eli Lilly Stock: New Analysis - 7 October
Fresh Eli Lilly information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
